Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. NVDA
4. PSKY
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. MSFT

Go back to Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026
(NASDAQ: AMLX) Delayed: 32.13 -0.28 (0.86%)
Previous Close $32.41    52 Week High $ 
Open $32.55    52 Week Low $ 
Day High $33.16    P/E N/A 
Day Low $31.90    EPS $ 
Volume 509,414